Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
no estimate extracted
13 participants
Moderate
Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Generic quality of life measures · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
no estimate extracted
13 participants
GRADE not reported
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Economic outcomes · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · patients with pain in Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with pain after 4 weeks · patients with pain in Guillain‐Barré syndrome
Methylprednisolone showed no clear difference in number of participants with pain after 4 weeks compared with placebo (low certainty).
1 finding from 1 review
Number of participants with decreased pain after 4 weeks · patients with pain in Guillain‐Barré syndrome
Methylprednisolone showed no clear difference in number of participants with decreased pain after 4 weeks compared with placebo (low certainty).
1 finding from 1 review
Number of participants with increased pain after 4 weeks · patients with pain in Guillain‐Barré syndrome
Methylprednisolone showed no clear difference in number of participants with increased pain after 4 weeks compared with placebo (low certainty).
1 finding from 1 review
Change in grip strength · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Sleeplessness · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to lower sleeplessness compared with oral prednisolone (low certainty).
1 finding from 1 review
Moon facies · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to lower moon facies compared with oral prednisolone (moderate certainty).
1 finding from 1 review
Change in disability after one year · patients with chronic inflammatory demyelinating polyradiculoneuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to higher remission at 12 months compared with oral prednisolone (moderate certainty).
1 finding from 1 review
≥ 1 point improvement on INCAT disability score at 12 months · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to higher ≥ 1 point improvement on INCAT disability score at 12 months compared with oral prednisolone (low certainty).
1 finding from 1 review
Change in MRC sum score · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Reduction in the amount of saliva production in the short term using an objective measure · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
no estimate extracted
1 participants
Very low
Quality of life · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
no estimate extracted
1 participants
Moderate